ID 2256 -
Jesion wyniosły
PL: Jesion wyniosły
EN: Fraxinus excelsior
Pdf: Fraxinus excelsior L.
1. Charakterystyka żywności / składnika
The food constituent that is the subject of the health claim is Fraxinus excelsior L.. The characterisation of Fraxinus excelsior L. is performed by comparing data provided as conditions of use to information extracted from standard reference textbooks (see Table 2 below and Appendix C for list of standard reference textbooks used for the characterisation).
Table 2. Information on Fraxinus excelsior L. from standard reference textbooks and the information provided as conditions of use.
Scientific name Part used Nature of the preparation
Conditions of use
Text-
book
Fraxinus
excelsior L.
Oleaceae
Leaf; bark
of the tree;
bud; shoot
Leaf:
Powder; tincture;
extracts; infusion;
Bark:
Extract; infusion
Bud; shoot:
Glycerinated
macerate
Dried leaf: min 2.5% total
hydroxy-cinnamic derivatives.
Leaf:
Tincture: 3 times 30 drops/day.
Dried extract (nebulisate): 1:4,
75-150 mg 3 times/day.
Infusion: 10-30 g/L of water.
Bark:
Note: dosage not specified.
Contains coumarine, glycosides
and derivatives.
ID
2256 Fraxinus excelsior
L.
Not
specified
Note: it is
assumed to
be the leaf
Dried extract
(nebulisate)
Dried extract (nebulisate): (1:4)
200-500 mg/day.
ID
3688 Fraxinus excelsior
L. - common
name: ash
Leaf Not specified
Note: it is assumed
to be dried leaf
Leaf: 5-20 g/day.
ID 2256:
The part used is not specified, but it is assumed that the nebulisate is from the leaves.
The Panel considers that the food constituent Fraxinus excelsior L., which is the subject of the health claim, has been sufficiently characterised with the following conditions of use: Dried leaf extract (nebulisate): (1:4) 200-500 mg/day.
ID 3688:
The nature of preparation is not specified, but it is assumed to be the dried leaf.
The Panel considers that the food constituent Fraxinus excelsior L., which is the subject of the health claim, has been sufficiently characterised with the following conditions of use: Dried leaf: 5-20 g/day.
2.1. Utrzymanie prawidłowego stanu stawów (ID 2256)
The claimed effect is “joint health”. The Panel assumes that the target population is the general population.
The claimed effect “joint health” is not sufficiently defined. In the context of the proposed wordings the Panel assumes that the claimed effect relates to maintenance of normal joints.
The Panel considers that maintenance of normal joints is beneficial to human health.
3.1. Utrzymanie prawidłowego stanu stawów (ID 2256)
Five references were cited to substantiate the claimed effect. Four of these are textbooks, monographs and a regulatory document in which the claimed effect is stated. One reference (Kostova and Iossifova, 2007) is a review on chemical composition of many Fraxinus species, including Fraxinus excelsior L. In this review the biological activity of extracts and pure compounds is shortly described but with no relation to the claimed effect. The Panel notes that the references cited did not provide any scientific data that could be used to substantiate the claimed effect.
The Panel concludes that a cause and effect relationship has not been established between the consumption of Fraxinus excelsior L. and maintenance of normal joints.
Warunki i możliwe ograniczenia stosowania oświadczenia
Nebulisate (1:4) 200-500 mg per day
